Care Fertility and U-Ploid Biotechnologies have announced a research collaboration focused on improving egg quality and fertility treatment outcomes. The partnership aims to address one of the main factors contributing to infertility, which deteriorates rapidly with increasing female age.
The collaboration will leverage Care Fertility’s clinical expertise and reputation for success rates, medical standards, and clinical leadership. This research has the potential to validate novel therapeutics and offer hope to millions of people struggling to conceive.
“We are thrilled to begin this collaborative research with U-Ploid Biotechnologies,” said Prof. Alison Campbell, Chief Scientific Officer of Care Fertility. “Advancing knowledge and treatments to support women facing age-related infertility is a priority for Care Fertility and to think that this research could help prevent the most common cause of infertility is extraordinary.”
For U-Ploid Biotechnologies, the collaboration is expected to accelerate the development of their lead program, a proprietary first-in-class therapeutic, enabling it to reach the clinical stage more quickly and efficiently.
“We are excited to partner with Care Fertility on this research as we enter the next stage of development,” said Dr. Jordan Abdi, Co-founder & CEO of U-Ploid Biotechnologies. “This collaboration provides us with the opportunity to work closely with a highly respected leader in fertility care and to gain valuable clinical insights.”
U-Ploid’s lead program has shown preclinical activity in addressing age-related natural egg deterioration. The collaboration represents a long-term research effort, with plans to enroll patients in the first study later this year.
